Clinical Trial Diversity in Oncology: FDA Takes Action with Post-Marketing Requirements or Commitments

Area of Science:

• Oncology
• Clinical Trials
• Health Equity

Background:

• Racial and ethnic minority groups are historically underrepresented in oncology clinical trials.
• The U.S. Food and Drug Administration (FDA) has highlighted this disparity, impacting drug approval and applicability.
• Recent initiatives emphasize the need for diversity in clinical trial participation.

Purpose of the Study:

• To analyze post-marketing studies mandated by the FDA's Office of Oncologic Diseases (OOD) concerning racial and ethnic minority inclusion.
• To assess the FDA's recent focus on diversity plans and post-approval requirements for oncology drugs.
• To underscore the necessity of increasing diverse patient enrollment in cancer clinical trials.

Main Methods:

• Review of post-marketing studies issued by the FDA's Office of Oncologic Diseases since 2020.
• Analysis focused on studies specifically requesting data on racial and ethnic minorities.
• Examination of FDA guidance and requirements related to diversity in clinical trials.

Main Results:

• The FDA has increasingly issued post-marketing requirements or commitments regarding diversity since 2020.
• Analysis confirmed a persistent need to improve the enrollment of diverse patient populations in cancer clinical trials.
• Existing FDA guidance recommends broadening eligibility and employing inclusive practices for trial diversity.

Conclusions:

• There is a clear and ongoing need to enhance the participation of racial and ethnic minorities in oncology clinical trials.
• FDA's post-marketing requirements signal a growing emphasis on ensuring trial populations reflect general population demographics.
• Further strategies are essential to achieve equitable representation in cancer research and improve outcomes for all patient groups.